- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00142220
The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients
September 8, 2006 updated by: University Medicine Greifswald
Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients
We study whether an increased proportion of omega-3-fatty acids (contained in fish oil) in the nutrition of critically ill patients reduces systemic inflammation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
160
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Greifswald, Germany, 17475
- Internistische ITS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- indication for parenteral nutrition
Exclusion Criteria:
- hypertriglyceridemia
- coagulation disorder
- decompensated liver cirrhosis or acute liver failure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
level of IL-6 in serum
|
HLA-expression on monocytes
|
Secondary Outcome Measures
Outcome Measure |
---|
mortality
|
number of nosocomial infections
|
days on mechanical ventilation
|
duration of ICU stay
|
SOFA score
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sigrun Friesecke, Dr., University Medicine Greifswald
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Study Registration Dates
First Submitted
August 31, 2005
First Submitted That Met QC Criteria
September 1, 2005
First Posted (Estimate)
September 2, 2005
Study Record Updates
Last Update Posted (Estimate)
September 11, 2006
Last Update Submitted That Met QC Criteria
September 8, 2006
Last Verified
September 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OMEGAVEN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis Syndrome
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
-
Oslo University HospitalRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, SevereNorway
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Cliniques universitaires Saint-Luc- Université...TerminatedMultiple Organ Dysfunction Syndrome | SEPTIC SHOCK | SEPSIS SYNDROMEBelgium
-
Maimónides Biomedical Research Institute of CórdobaUnknown
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Charalambos .A. GogosUniversity Hospital of Patras; Hellenic Society for Chemotherapy : Hellenic...Completed
Clinical Trials on Defined percentage of omega-3-fatty acids
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
S.LAB (SOLOWAYS)Center of New Medical Technologies; Triangel ScientificCompletedLDL Hyperlipoproteinemia | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Triglyceride Storage Type I or II DiseaseRussian Federation
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted
-
Wen-Chih WuWithdrawnSteatosis | Right Ventricular Failure | Pulmonary; HypertensionUnited States
-
University of California, San FranciscoAutism SpeaksCompleted
-
Pennington Biomedical Research CenterCompleted
-
Evandro Chagas Institute of Clinical ResearchAndrea Silvestre de Sousa, MD PhD; Pedro Emmanuel Alvarenga Americano do Brasil... and other collaboratorsCompletedChagas CardiomyopathyBrazil
-
Hugo W. Moser Research Institute at Kennedy Krieger...University of California, San FranciscoCompletedAutism Spectrum Disorders | HyperactivityUnited States
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.CompletedInfant DevelopmentUnited States
-
Centre for Chronic Disease Control, IndiaCompleted